drugset / Trial / NCT01525628
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the drug-drug interactions between BI 201335 and BI 207127 as well as their combined effect on CYP probe drug substrates and on tenofovir and raltegravir in treatment naive or prior treatment relapse patients with chronic hepatitis C infection.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-12
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caffeine | Small molecule | — | — |
| Subject | Deleobuvir | Small molecule | 600 mg | Oral |
| Subject | Faldaprevir | Small molecule | 120 mg | Oral |
| Subject | Midazolam | Small molecule | — | — |
| Subject | Tenofovir | Small molecule | — | — |
| Subject | Tolbutamide | Small molecule | — | — |
| Background | Pegylated Interferon | Unknown | — | — |
| Background | Ribavirin | Small molecule | — | — |